argenx Future Growth

Future criteria checks 5/6

argenx is forecast to grow earnings and revenue by 56.1% and 24.7% per annum respectively. EPS is expected to grow by 53.3% per annum. Return on equity is forecast to be 13.5% in 3 years.

Key information

56.1%

Earnings growth rate

53.3%

EPS growth rate

Biotechs earnings growth	24.1%
Revenue growth rate	24.7%
Future return on equity	13.5%
Analyst coverage	Good
Last updated	26 Apr 2024

Recent future growth updates

No updates

Recent updates

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion

Feb 01

Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod

Sep 21

argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers

Nov 30

argenx: R&D Day Goes Unnoticed

Aug 23

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

Jun 30

Argenx to regain global rights to cusatuzumab from Janssen Pharmaceuticals

Jun 07

Argenx raises ~$1B in global offering

Feb 03

argenx to raise $750M in proposed global offering

Feb 01

argenx on target to file efgartigimod applications in Japan and Europe

Jan 08

argenx and Zai Lab collaborate for Efgartigimod in Greater China

Jan 06

Argenx inks $98M deal to secure accelared review status for efgartigimod

Nov 23

argenx (ARGX) Investor Presentation - Slideshow

Nov 18

Earnings and Revenue Growth Forecasts

NasdaqGS:ARGX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	3,219	784	362	523	22
12/31/2025	2,451	234	240	198	28
12/31/2024	1,799	-146	-74	-283	29
12/31/2023	1,269	-295	-464	-420	N/A
9/30/2023	1,029	-234	N/A	N/A	N/A
6/30/2023	835	-397	-758	-654	N/A
3/31/2023	639	-511	N/A	N/A	N/A
12/31/2022	441	-710	-967	-863	N/A
9/30/2022	286	-909	N/A	N/A	N/A
6/30/2022	146	-907	-874	-876	N/A
3/31/2022	381	-595	N/A	N/A	N/A
12/31/2021	528	-408	-728	-607	N/A
9/30/2021	510	-373	N/A	N/A	N/A
6/30/2021	526	-319	-601	-474	N/A
3/31/2021	206	-573	N/A	N/A	N/A
12/31/2020	62	-608	-404	-398	N/A
9/30/2020	75	-535	N/A	N/A	N/A
6/30/2020	70	-359	-263	-255	N/A
3/31/2020	73	-275	N/A	N/A	N/A
12/31/2019	93	-181	105	152	N/A
9/30/2019	72	-109	N/A	N/A	N/A
6/30/2019	68	-104	188	230	N/A
3/31/2019	70	-47	N/A	N/A	N/A
12/31/2018	33	-76	-62	-62	N/A
9/30/2018	41	-56	N/A	N/A	N/A
6/30/2018	44	-47	-57	-57	N/A
3/31/2018	50	-46	N/A	N/A	N/A
12/31/2017	49	-34	-44	-44	N/A
9/30/2017	42	-30	N/A	N/A	N/A
6/30/2017	39	-25	N/A	-31	N/A
3/31/2017	23	-29	N/A	N/A	N/A
12/31/2016	18	-22	N/A	11	N/A
9/30/2016	17	-20	N/A	N/A	N/A
6/30/2016	14	-17	N/A	16	N/A
3/31/2016	12	-17	N/A	N/A	N/A
12/31/2015	11	-17	N/A	-15	N/A
9/30/2015	10	-16	N/A	N/A	N/A
6/30/2015	9	-14	N/A	-10	N/A
3/31/2015	7	-12	N/A	N/A	N/A
12/31/2014	7	-12	N/A	-6	N/A
9/30/2014	6	-10	N/A	N/A	N/A
6/30/2014	7	-8	N/A	-6	N/A
3/31/2014	7	-9	N/A	-8	N/A
12/31/2013	7	-8	N/A	-9	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARGX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: ARGX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ARGX is expected to become profitable in the next 3 years.

Revenue vs Market: ARGX's revenue (24.7% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: ARGX's revenue (24.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ARGX's Return on Equity is forecast to be low in 3 years time (13.5%).

argenx Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Recent updates

argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion

argenx SE Announces Approval of VYVDURA (efgartigimod Alfa and Hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE, Annual General Meeting, May 07, 2024

argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

argenx SE Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

argenx SE Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis

Argenx Se Announces 20 Presentations of Clinical Trial and Real-World Data from Studies of Vyvgart® and Vyvgart Hytrulo® (Vyvgart) in Neuromuscular Autoimmune Disease

Argenx Announces VYVGART (Efgartigimod Alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

argenx SE to Report Fiscal Year 2023 Results on Feb 29, 2024

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

argenx SE Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo Injection for Subcutaneous Use in Generalized Myasthenia Gravis

argenx SE Receives Notification of PDUFA Date Extension for SC Efgartigimod

argenx SE Announces Werner Lanthaler Will Resign as Non-Executive Director of Board and Chair of Audit and Compliance Committee

argenx SE Appoints Ana Cespedes as Non-Executive Director to Its Board of Directors

argenx SE Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

argenx SE Announces the Retirement of Hans De Haard as Chief Scientific Officer

argenx SE to Report Q3, 2023 Results on Oct 27, 2023

argenx SE Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis

Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod

argenx Appoints Camilla Sylvest to Board of Directors

Argenx Announces European Commission Approval of VYVGART(TM) (Efgartigimod Alfa-Fcab) for the Treatment of Generalized Myasthenia Gravis

Argenx's neuromuscular disorder drug Vyvgart wins approval in EU

Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M

argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe

argenx: A Very Good Start For Vyvgart

argenx SE Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain

argenx SE Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

Argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART (Efgartigimod Alfa-Fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting

argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting

argenx SE, Annual General Meeting, May 10, 2022

argenx SE, Annual General Meeting, May 10, 2022

argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers

argenx SE to Report Q3, 2022 Results on Oct 27, 2022

argenx SE to Report Q4, 2021 Results on Mar 03, 2022

argenx Announces VYVGART Approval in Japan for the Treatment of Generalized Myasthenia Gravis

argenx: Vyvgart's Approval A Key Step For Continued Value Creation

Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers

argenx: R&D Day Goes Unnoticed

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

argenx Announces Publication of Phase 3 ADAPT Trial Results of Efgartigimod for the Treatment of Generalized Myasthenia Gravis in the Lancet Neurology

Argenx to regain global rights to cusatuzumab from Janssen Pharmaceuticals

argenx SE Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis

argenx Issues Statement Concerning Efgartigimod

Argenx raises ~$1B in global offering

argenx SE Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

argenx to raise $750M in proposed global offering

argenx Announcea Interim Data from the Phase 2 Culminate Trial of cusatuzumab in Development with Cilag GmbH International

argenx on target to file efgartigimod applications in Japan and Europe

argenx SE and Zai Lab Limited Announce an Exclusive License Agreement for the Development and Commercialization of efgartigimod in Greater China, Including Mainland China, Hong Kong, Taiwan and Macau

argenx and Zai Lab collaborate for Efgartigimod in Greater China

Argenx inks $98M deal to secure accelared review status for efgartigimod

argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience

argenx (ARGX) Investor Presentation - Slideshow

argenx Announces Partnership with Chugai and the Clayton Foundation

argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies